77673768 - OXFORD BIOMEDICA

Information

• Trademark
• 77673768

• Source

• Serial Number

  77673768

• Registration Number

  3968293

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 10 - Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  February 19, 2009
  15 years ago

• Registration Date

  May 31, 2011
  13 years ago

• Transaction Date

  February 13, 2018
  6 years ago

• Status Date

  January 05, 2018
  6 years ago

• Published for Opposition Date

  March 15, 2011
  13 years ago

• Location Date

  May 31, 2011
  13 years ago

• Status Code

  710

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  SINGH, TEJBIR

• Attorney Docket Number

  14058

  Attorney Name

  Howard N. Aronson

  Law Office Assigned Location Code

  L60

• Owners

  • OXFORD BIOMEDICA (UK) LIMITED

Case File Statements

• D10000: "OXFORD"
• GS0011: Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; polypeptides for in vitro research use, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory, scientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, namely, in vitro and in vivo use
• GS0051: Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparations, for use in gene therapy and for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders
• GS0101: Instruments and apparatus for the administration of pharmaceutical, gene therapy and/or vaccine preparations and substances, namely, medical syringes and injectors for medical purposes
• GS0421: Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development for new products in the field of biotechnology, advisory services relating to gene therapy products and clinical trials, conducting clinical trials
• GS0441: Medical services; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders and contraceptives
• PM0000: OXFORD BIO MEDICAL

Case File Event Statements

• 1/5/2018 - 6 years ago

  34 - CANCELLED SEC. 8 (6-YR) Type: C8..

• 5/31/2011 - 13 years ago

  33 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 3/15/2011 - 13 years ago

  32 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 3/15/2011 - 13 years ago

  31 - PUBLISHED FOR OPPOSITION Type: PUBO

• 2/8/2011 - 13 years ago

  30 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 1/31/2011 - 13 years ago

  29 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 1/31/2011 - 13 years ago

  28 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 1/31/2011 - 13 years ago

  27 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 1/31/2011 - 13 years ago

  26 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 1/31/2011 - 13 years ago

  25 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 1/6/2011 - 13 years ago

  24 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 1/6/2011 - 13 years ago

  23 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 1/6/2011 - 13 years ago

  22 - ASSIGNED TO LIE Type: ALIE

• 12/9/2010 - 13 years ago

  21 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI

• 6/14/2010 - 14 years ago

  20 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2

• 6/14/2010 - 14 years ago

  19 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI

• 6/14/2010 - 14 years ago

  18 - SUSPENSION INQUIRY WRITTEN Type: CNSI

• 12/11/2009 - 14 years ago

  17 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 12/11/2009 - 14 years ago

  16 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 12/11/2009 - 14 years ago

  15 - SUSPENSION LETTER WRITTEN Type: CNSL

• 12/1/2009 - 14 years ago

  14 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 12/1/2009 - 14 years ago

  13 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 12/1/2009 - 14 years ago

  12 - SUSPENSION LETTER WRITTEN Type: CNSL

• 11/20/2009 - 14 years ago

  11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 11/20/2009 - 14 years ago

  10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 11/20/2009 - 14 years ago

  9 - ASSIGNED TO LIE Type: ALIE

• 11/9/2009 - 15 years ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 5/11/2009 - 15 years ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 5/11/2009 - 15 years ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 5/11/2009 - 15 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 5/11/2009 - 15 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 2/24/2009 - 15 years ago

  3 - NOTICE OF PSEUDO MARK MAILED Type: MPMK

• 2/23/2009 - 15 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 2/23/2009 - 15 years ago

  1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP